CPHI Concludes Successfully | Tongjun Pharmaceutical Connects Global Clients Through Innovative Peptide Technology
Publish Time:
2026-07-07
From June 16 to 18, 2026, the 24th CPHI & PMEC China—the World Pharmaceutical Ingredients Exhibition—concluded successfully at the Shanghai New International Expo Center. With an exhibition space of 240,000 square meters, the event brought together more than 3,600 premium suppliers from around the globe and attracted over 110,000 professional visitors from both domestic and international markets, further underscoring its status as Asia’s premier annual gathering for the pharmaceutical industry.
As a seasoned leader in the field of peptide synthesis, Tongjun Pharmaceuticals brings forth EMPHASES. ® Innovation Liquid-phase peptide synthesis The company showcased its cutting-edge technologies and a comprehensive GLP‑1 product portfolio at booth W9A25, marking a highlight moment for peptide technology throughout the three-day exhibition.
On-site Coverage
Huge popularity, lively negotiations.
During the exhibition, the Tongjun Pharmaceutical booth maintained steadily rising popularity. Pharmaceutical companies and API buyers from Europe and North America, Southeast Asia, South Asia, as well as China itself, CRO/ CDMO Institutions kept arriving in droves, with a steady stream of inquiries at the exhibition booth and every seat at the negotiation table fully occupied.
▲ The Tongjun Pharmaceutical team at W9A25 Booth
Over the course of three days, the technical team engaged in in-depth discussions with hundreds of domestic and international clients. From… Semaglutide From the large-scale supply of intermediates and the custom synthesis of tirzepatide fragments, to… EMPHASES ® Platform’s technology licensing partnerships—each conversation revolves around a central premise: How to make high-quality peptides more affordable.
EMPHASES ® Innovative Liquid-Phase Peptide Synthesis Platform
World’s first green, high-efficiency, scalable technology reduces costs to one-third of those for solid-state solutions.
Our independently developed liquid-phase peptide synthesis technology platform has overcome the scalability limitations of traditional solid-phase synthesis. Leveraging this platform, Tongjun Pharmaceutical has successfully achieved the efficient production of high‑impact peptides such as semaglutide and tirzepatide, offering customers end-to-end technical services that encompass process development, quality research, and scale‑up manufacturing.
▲ GLP-1 Sidechain Product Line Showcase
GLP-1 Side Chain Series
High-purity batches are stable, available in ton-scale quantities, and cost‑controlled.
· AEEA / AEEA-AEEA
· Fmoc-AEEA-OH / Fmoc-AEEA-AEEA-OH
· tBuO-C18-Glu(OtBu)-AEEA-AEEA-OH / tBuO-C20-Glu(OtBu)-AEEA-AEEA-OH
Short-peptide intermediate
Sequence‑Precise Isomer Control with Flexible Protecting Group Strategy
· Fmoc-His-Aib-OH / Fmoc-Ile-Aib-OH
· Fmoc-Tyr(tBu)-Aib-OH / Fmoc-Glu(OtBu)-Aib-OH
· Boc-L-His(Trt)-Aib-OH, etc.
Tirzepatide full-length fragment
One-stop supply with quality traceability and custom synthesis support.
Coverage Tirzepatide synthesis The required peptide fragments and intermediates meet diverse needs, from kilogram‑scale R&D to ton‑scale scale‑up, helping clients advance their project pipelines efficiently.
SNAC oral permeation enhancer
Clinically validated key excipients for oral peptides
SNAC (Salcaprozate Sodium), a key excipient for oral semaglutide, is supplied by Jun Pharmaceutical in high quality and in compliance with regulatory standards, supporting customers in advancing the development and commercialization of oral peptide formulations.
Pharmaceutical Peptides & Cosmetic Peptides
Third-party verification of the effectiveness of patent protection for independent brands
Pharmaceutical peptides — Semaglutide, Tirzepatide
Beauty peptides ——CG Oligo-1, Whitide ® Ⅰ Nine-peptide-1, CG GHK-Cu copper peptide, CG Arg acetyl hexapeptide-8, CG Pal-GHK palmitoyl tripeptide-1
Beauty-enhancing active ingredients
· Bisyne ® Bose–Einstein statistics
· CG HPR Ultra-Vision A / CG Retinol Retinol
· CG Chroman'6 ® Chromanol
· Dihydro-avenanthramide
Although the exhibition has concluded, the ties between Tongjun Pharmaceutical and its global partners are only just beginning to strengthen.
During the industry’s window of opportunity, as semaglutide patents are set to expire one after another in 2026, the global GLP‑1 supply chain is at a critical juncture of reshaping. Tongjun Pharmaceutical, with EMPHASES… ® Grounded in innovative liquid-phase technologies and underpinned by flexible supply capabilities ranging from kilogram to ton scales, we are committed to building a resilient GLP‑1 peptide supply chain, ensuring that sustainable, affordable peptides truly contribute to human beauty and health.
Whether seeking large-scale supply of semaglutide intermediates, exploring joint development of tirzepatide manufacturing processes, or addressing EMPHASES… ® Platform Technology Licensing Collaboration — Tongjun Pharmaceuticals looks forward to partnering with you to jointly build a new frontier in the peptide industry.
Thank you to all our industry peers for your trust and support!
The CPHI exhibition has concluded successfully, but Tongjun Pharmaceutical’s commitment to technological innovation and customer support remains unwavering.
Tongjun Pharmaceutical
Sustainable and affordable peptides
Beauty and health that benefit humanity
Contact Us
If you missed the live session, or if you’re facing technical challenges in peptide synthesis or have needs related to securing the GLP‑1 supply chain, please feel free to contact us at any time.
Contact: Tongjun Pharmaceutical Marketing Department
Contact number: +86 13380081396
Service Hotline: 020-82350801
Email: marketing@congenpharm.com
Official website: www.congenpharm.com
ABOUT US
Guangzhou Tongjun Pharmaceutical Technology Co., Ltd. (CongenPharma) Founded in 2013 and headquartered in Guangzhou, the company is a technology‑driven enterprise specializing in the R&D and industrialization of peptide APIs and intermediates, as well as cosmetic peptides. The company possesses… 40+ items Domestic and international patents, 2,000+㎡ Research and Development Center and 12,000+㎡ Production base.
Independently established the world’s first EMPHASES ® Innovative Liquid-Phase Peptide Synthesis Platform and has established five major application‑technology platforms: water‑solubility enhancement, demand‑responsive release, nano‑lock control, dual stabilization, and peptide‑based drug delivery. Its core business spans the entire GLP‑1 value chain, cosmetic peptides, and beauty‑enhancing active ingredients, with a mission to become a globally renowned leader in the peptide field.
Integrity as Our Foundation · Innovation for Lasting Success · United in Purpose · Co-Creating Timeless Excellence
CongenPharma
Gain insights into cutting-edge peptide synthesis technologies · Stay abreast of the latest developments in the GLP‑1 industry chain · Master innovative applications of cosmetic peptides
Making sustainable, affordable peptides accessible to all, for the beauty and health of humanity.
Prev:
Relevant Information
undefined
